ES2149952T3 - L-arginina y analogos como inhibidores de la agregacion de trombocitos. - Google Patents

L-arginina y analogos como inhibidores de la agregacion de trombocitos.

Info

Publication number
ES2149952T3
ES2149952T3 ES95900714T ES95900714T ES2149952T3 ES 2149952 T3 ES2149952 T3 ES 2149952T3 ES 95900714 T ES95900714 T ES 95900714T ES 95900714 T ES95900714 T ES 95900714T ES 2149952 T3 ES2149952 T3 ES 2149952T3
Authority
ES
Spain
Prior art keywords
arginine
inhibitors
analogs
thrombocyte aggregation
thrombocyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900714T
Other languages
English (en)
Inventor
Jurgen C Prof Dr Med Frolich
Rainer H Boger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2149952T3 publication Critical patent/ES2149952T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A LA UTILIZACION DE L-ARGININA Y SUS DERIVADOS COMO INHIBIDORES DE AGREGACION DE TROMBOCITOS PARA TRATAMIENTO DE PERTURBACIONES DE CIRCULACION CENTRAL Y PERIFERICAS, ASI COMO EL RECHAZO DE ORGANOS TRASPLANTADOS. ESTOS COMPUESTOS PUEDEN ALIVIAR LOS SINTOMAS PRODUCIDOS EN ESTAS CONDICIONES.
ES95900714T 1993-11-12 1994-11-11 L-arginina y analogos como inhibidores de la agregacion de trombocitos. Expired - Lifetime ES2149952T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4338793A DE4338793A1 (de) 1993-11-12 1993-11-12 L-Arginin und Analoge als Thrombozytenaggregationshemmer

Publications (1)

Publication Number Publication Date
ES2149952T3 true ES2149952T3 (es) 2000-11-16

Family

ID=6502515

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95900714T Expired - Lifetime ES2149952T3 (es) 1993-11-12 1994-11-11 L-arginina y analogos como inhibidores de la agregacion de trombocitos.

Country Status (5)

Country Link
EP (1) EP0679080B1 (es)
AT (1) ATE194282T1 (es)
DE (2) DE4338793A1 (es)
ES (1) ES2149952T3 (es)
WO (1) WO1995013060A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
ATE456302T1 (de) * 1997-09-17 2010-02-15 Strategic Science & Technologi Verabreichung von arginin zur erwärmung von kaltem/kühlem gewebe
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
WO2001057184A2 (en) * 2000-02-01 2001-08-09 Vanderbilt University Use of platelet activity modulators for inhibiting complement activation
DE10128934A1 (de) * 2001-06-18 2003-02-06 Bernhard Sibbe Wirkstoffzusammensetzung zur Vorbeugung gegen Angina-Pectoris-Beschwerden
WO2005102307A2 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
KR101643797B1 (ko) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 이부프로펜을 함유하는 국소 조성물
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
EP4491225A3 (en) 2010-12-29 2025-03-26 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308257A (en) * 1980-06-03 1981-12-29 Saul Caspe Accelerating cellular repair composition for the human body and method of administering same
US4732892A (en) * 1985-07-12 1988-03-22 American Home Products Corporation L-α-amino acids as transdermal penetration enhancers
US5053387A (en) * 1987-02-20 1991-10-01 Shriners Hospitals For Crippled Children Omega-3 fatty acids in traumatic injury treatment
EP0320976A1 (en) * 1987-12-18 1989-06-21 Ajinomoto Co., Inc. Arginine derivatives and cosmetic compositions comprising the same
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
JPH05163139A (ja) * 1991-12-12 1993-06-29 Ajinomoto Co Inc 抗動脈硬化剤
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung

Also Published As

Publication number Publication date
ATE194282T1 (de) 2000-07-15
DE4338793A1 (de) 1995-05-18
EP0679080B1 (de) 2000-07-05
EP0679080A1 (de) 1995-11-02
WO1995013060A1 (de) 1995-05-18
DE59409421D1 (en) 2000-08-10

Similar Documents

Publication Publication Date Title
ES2149952T3 (es) L-arginina y analogos como inhibidores de la agregacion de trombocitos.
DE69200685D1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3-Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten.
RU94029662A (ru) Фосфонооксиметиловые эфиры производных таксана, фармацевтическая композиция, способы лечения
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE157251T1 (de) Verwendung von inositoltriphosphat zur behandlung von entzündungen
RU94002482A (ru) Пятичленные гетероциклы, смесь их изомеров или отдельные изомеры и их соли
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
FR2446832A1 (fr) Octahydro-pyrazolo(3,4-g)quinoleines et leur utilisation therapeutique
ATE102930T1 (de) Heterozyklische verbindungen, deren herstellung und medikamente diese enthaltend.
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE59007531D1 (de) Verwendung des Wirkstoffs Azelastin zur Bekämpfung von Psoriasis-Erkrankungen.
ATE16489T1 (de) Aroylimidazolone.
FR2365553A1 (fr) Derives amides de pentapeptides et tetrapeptides et leur utilisation comme medicaments
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
ES2135769T3 (es) Derivados de isotiourea como inhibidores de no-sintasa.
ES2104821T3 (es) Cetoacidos que contienen quinoleina como antagonistas de leucotrienos.
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
NO965097L (no) Nye elastaseinhibitorer
ATE59781T1 (de) Potenzierung von prazosin.
MX9300205A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
DE69327207D1 (de) Tryptamine zur Behandlung von Störungen der circadianen Rhythmik
FR2362852A1 (fr) Derives de la phenothiazine, leur preparation et leurs utilisations therapeutiques
BG98238A (bg) Заместени бензотиазолови производни,получаванетоим и приложението им като хербициди
DE68918479D1 (de) Menschlicher Hitzeschock-Faktor.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 679080

Country of ref document: ES